Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT01620216 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2021-11-04
Summary
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, sunitinib malate, sorafenib tosylate, ponatinib hydrochloride, pacritinib, ruxolitinib, and idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- OTHER
-
Antitumor Drug Screening Assay
Undergo pre clinical kinase inhibitor activity screening
- DRUG
-
Given PO
- DRUG
-
Idelalisib
Given PO
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- DRUG
-
Pacritinib
Given PO
- OTHER
-
Pharmacological Study
Correlative studies
- DRUG
-
Ponatinib
Given PO
- DRUG
-
Ponatinib Hydrochloride
Given PO
- DRUG
-
Given PO
- DRUG
-
Given PO
- DRUG
-
Sorafenib Tosylate
Given PO
- DRUG
-
Sunitinib
Given PO
- DRUG
-
Sunitinib Malate
Given PO
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Oregon Health and Science University
collaborator OTHER -
OHSU Knight Cancer Institute
lead OTHER
Principal Investigators
-
Marc Loriaux · OHSU Knight Cancer Institute
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-11
- Primary Completion
- 2017-04-25
- Completion
- 2017-04-30
Countries
- United States
Study Locations
More Related Trials
-
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04155580 ·Status: TERMINATED ·Phase: PHASE1
-
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
NCT02420717 ·Status: TERMINATED ·Phase: PHASE2
-
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00475150 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01664897 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
NCT00005942 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT01550185 ·Status: TERMINATED ·Phase: PHASE1
-
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02129062 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
NCT03677596 ·Status: COMPLETED ·Phase: PHASE4
-
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
NCT00703300 ·Status: COMPLETED ·Phase: PHASE1
-
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
NCT02551718 ·Status: COMPLETED ·Phase: NA
-
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
NCT00362466 ·Status: TERMINATED ·Phase: PHASE3
-
Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02882321 ·Status: TERMINATED ·Phase: PHASE1
-
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
NCT00015860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT02091245 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
NCT01861314 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
NCT07011004 ·Status: RECRUITING ·Phase: PHASE1
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
NCT00702403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
NCT05521087 ·Status: WITHDRAWN ·Phase: PHASE1
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290 ·Status: WITHDRAWN ·Phase: PHASE3
-
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
NCT03628053 ·Status: WITHDRAWN ·Phase: PHASE3
-
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
NCT00816283 ·Status: COMPLETED ·Phase: PHASE1